A skin health specialist, which raised £4.5m when it listed on the London stock market last week, will use the funds to drive forward its probiotic technology for skin health applications.
SkinBioTherapeutics, a University of Manchester spin-out, will focus on developing and commercialising its SkinBiotix technology platform.
The funds raised will enable it to focus on its development portfolio of three programmes – in skin care (sensitive skin), anti-infection and eczema.
This article is for information purposes only.
Please remember that financial investments may rise or fall and past performance does not guarantee future performance in respect of income or capital growth; you may not get back the amount you invested.
There is no obligation to purchase anything but, if you decide to do so, you are strongly advised to consult a professional adviser before making any investment decisions.